First therapeutic specifically indicated for aTTP seeks authorization

Ablynx submits a marketing authorisation application to the European Medicines Agency for Caplacizumab, for the treatment of aTTP. If approved, it will be the first therapeutic specifically indicated for the treatment of aTTP.

View the full press release.